{"id":"aa-fdc","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Pruritus"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Artesunate is an artemisinin derivative that generates reactive oxygen species to damage Plasmodium parasites, while amodiaquine is a 4-aminoquinoline that inhibits heme polymerization and parasite protein synthesis. Together in fixed-dose combination, they provide synergistic antimalarial activity with reduced risk of resistance development compared to monotherapy.","oneSentence":"AA(FDC) is a fixed-dose combination antimalarial therapy containing artesunate and amodiaquine that works by disrupting parasite metabolism and preventing malaria infection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:26:03.913Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Uncomplicated malaria caused by Plasmodium falciparum"},{"name":"Malaria treatment in endemic regions, particularly in sub-Saharan Africa"}]},"trialDetails":[{"nctId":"NCT02831764","phase":"PHASE3","title":"An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2016-07-18","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":722},{"nctId":"NCT02831673","phase":"PHASE3","title":"An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2016-07-21","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":719},{"nctId":"NCT02738931","phase":"PHASE1","title":"Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2016-05","conditions":"Infection, Human Immunodeficiency Virus","enrollment":30},{"nctId":"NCT00902811","phase":"PHASE4","title":"Effectiveness of Artemisinin Combination Regimens in Falciparum Malaria","status":"UNKNOWN","sponsor":"Medecins Sans Frontieres, Netherlands","startDate":"2008-12","conditions":"Uncomplicated Falciparum Malaria","enrollment":600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":196,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Artesunate Amodiaquine Winthrop® Sanofi Aventis"],"phase":"marketed","status":"active","brandName":"AA(FDC)","genericName":"AA(FDC)","companyName":"Medecins Sans Frontieres, Netherlands","companyId":"medecins-sans-frontieres-netherlands","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AA(FDC) is a fixed-dose combination antimalarial therapy containing artesunate and amodiaquine. Used for Uncomplicated malaria caused by Plasmodium falciparum, Malaria treatment in endemic regions.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}